Refine
Year of publication
Document Type
- Article (848)
- Preprint (720)
- Part of Periodical (21)
- Conference Proceeding (9)
- Working Paper (8)
- Review (3)
- Book (1)
- Part of a Book (1)
- Contribution to a Periodical (1)
- Report (1)
Language
- English (1589)
- German (23)
- Multiple languages (1)
Has Fulltext
- yes (1613)
Is part of the Bibliography
- no (1613)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron scattering (experiments) (12)
- Hadron-Hadron Scattering (11)
- LHC (9)
- Heavy-ion collision (6)
- Jets (5)
- ALICE experiment (4)
- Collective Flow (4)
- Inverse kinematics (4)
- Quark-Gluon Plasma (4)
- Quasi-free scattering (4)
- immunotherapy (4)
- ALICE (3)
- Breast cancer (3)
- COVID-19 (3)
- Diffraction (3)
- Elastic scattering (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- Nuclear reactions (3)
- Polarization (3)
- Radiotherapy (3)
- Spectroscopic factors (3)
- acute myeloid leukemia (3)
- breast cancer (3)
- cirrhosis (3)
- cytokine-induced killer cells (3)
- global change (3)
- portal hypertension (3)
- pp collisions (3)
- screening (3)
- 140Ce (2)
- AML (2)
- Abdominal aortic aneurysm (2)
- Abdominelles Aortenaneurysma (2)
- Accelerators & Beams (2)
- Acute myeloid leukemia (2)
- Adaptive Erwartung (2)
- Aspergillus (2)
- Atomic, Molecular & Optical (2)
- Atrial fibrillation (2)
- Außenwirtschaftliches Gleichgewicht (2)
- Beauty production (2)
- Bipolar disorder (2)
- CIK cells (2)
- Charm physics (2)
- Cirrhosis (2)
- Clinical Global Impression of Change (2)
- Community ecology (2)
- Diagnostik (2)
- Dravet syndrome (2)
- Dynamisches Gleichgewicht (2)
- Ecological networks (2)
- Elliptic flow (2)
- Embryos (2)
- Endovascular repair (2)
- Endovaskuläre Behandlung (2)
- Erwartungsbildung (2)
- Ewing sarcoma (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Heavy-ion collisions (2)
- Kalman filter (2)
- Klinische Ergebnisse (2)
- Konjunktur (2)
- Leistungsbilanz (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Liver diseases (2)
- MRI (2)
- Mammakarzinom (2)
- NK cells (2)
- NK-92 (2)
- Nachsorge (2)
- Neutropenia (2)
- News and Business Cycles (2)
- Non-small cell lung cancer (2)
- Offene Versorgung (2)
- Offene Volkswirtschaft (2)
- Open Economy DSGE Models (2)
- Open repair (2)
- Outcome (2)
- PTEN (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pneumonia (2)
- Predictive markers (2)
- Produktivität (2)
- Psychiatric disorders (2)
- Pulmonary embolism (2)
- QCD (2)
- Quarkonium (2)
- RHIC (2)
- Radiative capture (2)
- Real-time Data (2)
- Register (2)
- Registry (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Shell model (2)
- Single electrons (2)
- Single-particle states (2)
- Suicide (2)
- Surgery (2)
- Surgical oncology (2)
- Treatment outcome (2)
- Trend Growth (2)
- USA (2)
- Umfrage (2)
- Wirtschaftswachstum (2)
- X-ray crystallography (2)
- Zahlungsbilanzausgleich (2)
- Zahlungsbilanzungleichgewicht (2)
- allogeneic stem cell transplantation (2)
- biodiversity protection (2)
- boryl anions (2)
- childhood acute myeloid leukemia (2)
- chimeric antigen receptor (2)
- conservation funding (2)
- conservation planning (2)
- convulsive seizures (2)
- decision making (2)
- dentate gyrus (2)
- diagnosis (2)
- elderly (2)
- fenfluramine (2)
- follow‑up (2)
- guideline (2)
- homeostatic plasticity (2)
- household finance (2)
- liver transplantation (2)
- lung cancer (2)
- meningioma (2)
- post-2020 biodiversity targets (2)
- real-world (2)
- refugees (2)
- relapse (2)
- salvage therapy (2)
- soft tissue sarcoma (2)
- spine head (2)
- stability (2)
- status epilepticus (2)
- storage rings (2)
- strategic site selection (2)
- synaptic plasticity (2)
- synaptopodin (2)
- tumor necrosis factor (2)
- 2-aminobenzimidazole (1)
- 3D tissue models (1)
- 5 lipoxygenase (1)
- 9-borafluorene (1)
- 900 GeV (1)
- AB-serum (1)
- ABC transporters (1)
- ABCB1 (1)
- ABCC1 (1)
- ABCG2 (1)
- ACLF (1)
- ACURATE neo (1)
- ADGRE1 (1)
- ADHD (1)
- AGN host galaxies (1)
- AIS (1)
- ALICE detector (1)
- ALL (1)
- APRI (1)
- ARDS (1)
- ATM (1)
- ATPases (1)
- Abdominal infections (1)
- Accelerators & storage rings (1)
- Acquired drug resistance (1)
- Active middle ear implants (1)
- Acute calcolous cholecystitis (1)
- Acute coronary syndrome (1)
- Acute-on-chronic subdural hematoma (1)
- Advanced biliary tract cancer (1)
- Afrotheria (1)
- Allogeneic hematopoietic stem (1)
- Amino acid analysis (1)
- Angiogenesis (1)
- Animal flight (1)
- Animal phylogenetics (1)
- Anti-nuclei (1)
- Antibiotic (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- Aortic valve replacement (1)
- Arteria ophthalmica (1)
- Artesunate (1)
- Artificial Intelligence (1)
- Aspergillus fumigatus (1)
- Aspergillus species (1)
- Atomic & molecular beams (1)
- Atomic and Molecular Physics (1)
- Atoms (1)
- Auditory system (1)
- Autorschaft (1)
- B-slope (1)
- BI1361849 (1)
- BRAF (1)
- BRAF mutation (1)
- BRCA1 (1)
- BRCA2 (1)
- BTC (1)
- Beam loss (1)
- Bevacizumab (1)
- Big Data (1)
- Biliary tree stones (1)
- Biodiversity Data (1)
- Bioinformatics (1)
- Biological (1)
- Biological heart valves (1)
- Biomarker (1)
- Biomarkers (1)
- Biomonitoring (1)
- Bioprosthesis (1)
- Bird flight (1)
- Blindness (1)
- Blood plasma (1)
- Bloodstream infections (1)
- Bone conduction devices (1)
- Bone metastases (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Business strategy in drug development (1)
- C3M (1)
- C4M (1)
- CAKUT (1)
- CAR (1)
- CBA (1)
- CD3/CD19 depletion (1)
- CD36 (1)
- CDI (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CQL (1)
- CRVO (1)
- CTLA-4 (1)
- CV9202 (1)
- CVID (1)
- Caccoleptus (Bicaccoleptus) kacka, Nearctic region (1)
- Cancer (1)
- Cancer detection (1)
- Cancer treatment (1)
- Candida (1)
- Canopy height model (1)
- Capecitabine (1)
- Cardiac troponin (1)
- Catheter ablation (1)
- Cell membranes (1)
- Cell proliferation (1)
- Cell signalling (1)
- Cell-to-Cell Spread (1)
- Central Europe (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Chemotherapy (1)
- Cherenkov counter: lead-glass (1)
- Chickens (1)
- Chimerism (1)
- Cholecystectomy (1)
- Circadian (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Climate-change ecology (1)
- Clinical study (1)
- Clinical trial (1)
- Closure (1)
- Coalescence (1)
- Cohort studies (1)
- Coincidence measurement (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Collectivity (1)
- Colon capsule endoscopy (1)
- Colorectal cancer (1)
- Combined immune checkpoint blockade (1)
- Compact astrophysical objects (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Consensus (1)
- Consensus statement (1)
- Conservation (1)
- Coronary heart disease (1)
- Correlation (1)
- Couch tracking (1)
- Covid-19 (1)
- Critical care (1)
- Critical point (1)
- Cross sections (1)
- Cryoballoon (1)
- Cryoelectron microscopy (1)
- Cryoelectron tomography (1)
- Cultural Influences on Economic Behavior (1)
- Culture positive (1)
- Current Account (1)
- DNA sequence analysis (1)
- DNA-PK (1)
- DNA/LNA mixmers (1)
- DST (1)
- Data sharing (1)
- De-isolation (1)
- Death rates (1)
- Dermis (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Diagnostic markers (1)
- Digestive system procedures (1)
- Digital (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Digitization (1)
- Direct nuclear reactions (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Drug susceptibility testing (1)
- Drug therapy (1)
- EGFR (1)
- EGFR inhibitor (1)
- EMR1 (1)
- EPR (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- ESBL (1)
- Earth sciences (1)
- Ecological modelling (1)
- Ecology (1)
- Economics (1)
- Ecosystem ecology (1)
- Eicosanoids (1)
- Electromagnetic transitions (1)
- Electron-pion identification (1)
- Electronic cigarettes (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elephants (1)
- Ellenberg indicator values (1)
- Endocrinology (1)
- Endoscopic ultrasound (1)
- Endoscopy (1)
- Enterobacteriaceae (1)
- Epstein-Barr virus (1)
- Equity (1)
- Esophagectomy (1)
- Europe (1)
- European Dry Grassland Group (1)
- European Society for Immunodeficiencies (ESID) (1)
- Eutheria (1)
- Evidence-based guidelines (1)
- Evolutionary biology (1)
- Exosomes (1)
- Extended donor criteria (1)
- F4/80 (1)
- F508del homozygous (1)
- FDG-PET/CT (1)
- FHIR (1)
- FHIR Search (1)
- FIB-4 (1)
- Falciparum (1)
- Fast Healthcare Interoperability Resources (1)
- Fatty acids (1)
- Fatty liver (1)
- Fc receptor (1)
- Feathers (1)
- Femtoscopy (1)
- Festuco-Brometea (1)
- Fevers (1)
- Fibre/foam sandwich radiator (1)
- Fibroblast growth factor (1)
- Fibroblasts (1)
- Filler (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Fistula (1)
- Flow (1)
- Fmoc solid phase peptide synthesis (1)
- Follow-up (1)
- Forward physics (1)
- Fusarium (1)
- GWAS (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Galaxies and clusters (1)
- Galietalia veri (1)
- Gallbladder percutaneous drainage (1)
- Gene expression (1)
- Genetics (1)
- Genetics research (1)
- German PID-NET registry (1)
- Gimbaled tracking (1)
- Glabella (1)
- Glioblastoma (1)
- Glioblastoma survival (1)
- Gouvernementalität (1)
- Gram negative bacteria (1)
- Green fluorescent protein (1)
- Groomed jet radius (1)
- Guadeloupe Archipelago (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Guidelines (1)
- HADES (1)
- HBT (1)
- HBV (1)
- HER2-positive (1)
- HER2/neu (1)
- HIPPO signalling (1)
- HIV (1)
- HL7 FHIR (1)
- HNSCC (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Haematopoietic stem cells (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Head neck cancer (1)
- Health economics (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ion storage ring (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Hegemonie (1)
- Hematopoietic stem cell transplantation (1)
- Hepatitis c (1)
- Hepatocellular carcinoma (1)
- Herbaria (1)
- Hereditary breast cancer (1)
- Hereditary ovarian cancer (1)
- Hif-1 alpha (1)
- Hif1α (1)
- High-energy astrophysics (1)
- High-energy neutron detection (1)
- Higher moments (1)
- Hospitals (1)
- Household Finance (1)
- Household Portfolios (1)
- Hsp70 (1)
- Human behaviour (1)
- Hypofractionated radiotherapy (1)
- Hyraxes (1)
- ICU (1)
- IHC (1)
- IL-15 (1)
- IL-21 (1)
- IL-6 (1)
- IR (1)
- ISS (1)
- IgG substitution therapy (1)
- Immune response (1)
- Immunity (1)
- Immunogenetics (1)
- Immunology (1)
- Immunology and Microbiology Section (1)
- Immunomonitoring (1)
- Immunotherapy (1)
- In vitro (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Induction chemotherapy (1)
- Induction therapy (1)
- Infection (1)
- Inflammation (1)
- Influenza (1)
- Intensity interferometry (1)
- Intensive care units (1)
- Interference fragmentation function (1)
- Interleukin-17A (1)
- Intra-abdominal infection (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ions (1)
- Ipilimumab (1)
- Isoscalar giant resonances (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KLK5 (1)
- KOOS IV (1)
- KPS (1)
- Kidney diseases (1)
- Koelerio-Corynephoretea (1)
- LCH (1)
- Langerhans cell histiocytosis (1)
- Laparostomy (1)
- Library screening (1)
- Lifestyle (1)
- Literarischer Stil (1)
- Literaturwissenschaft (1)
- Liver (1)
- Liver cancer (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MACS (1)
- MCP-1 (1)
- MGMT (1)
- MLC tracking (1)
- MLL (1)
- MMP9 (1)
- MRP4 (1)
- MYC (1)
- Machine learning (1)
- Macrotomini (1)
- Magnetic resonance (1)
- Malaria (1)
- Mammalian genomics (1)
- Mammals (1)
- Material budget (1)
- Mechanisms of disease (1)
- Medical imaging (1)
- Melanoma (1)
- Menthol (1)
- Mesh (1)
- Metabolism (1)
- Methicillin-resistant Staphylococcus aureus (1)
- MicroRNAs (1)
- Microscopy (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mitoxantrone (1)
- Mixed hearing loss (1)
- Models & methods for nuclear reactions (1)
- Molecular diagnostic testing (1)
- Molecular medicine (1)
- Molecular neuroscience (1)
- Monitoring (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidrug-resistant organisms (1)
- Multimodal imaging (1)
- Multiomics (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Mutation databases (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- NADPH oxidase (1)
- NAFLD (1)
- NOTCH (1)
- NSCLC (1)
- NTM (1)
- Neoadjuvant therapy (1)
- Neoliberalismus (1)
- Neolithic (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Network analysis (1)
- Neural network (1)
- Neutron physics (1)
- Nicotine (1)
- Nivolumab (1)
- Non-trauma (1)
- Non-tuberculous mycobacteria (1)
- Nonflow (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nox1 (1)
- NoxO1 (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear resonance fluorescence (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- Nutrition (1)
- Obesity (1)
- Occlusion (1)
- Omics (1)
- Oncogenes (1)
- Oncology (1)
- One-nucleon removal (1)
- Open abdomen (1)
- Open pulmonary tuberculosis (1)
- Ophthalmoplegia (1)
- Opportunistic infections (1)
- Orbital electron capture (1)
- Organ allocation (1)
- Organ motion (1)
- Osteoporosis (1)
- Oxaliplatin (1)
- P2X7 receptor (1)
- PD-1 (1)
- PDGFRβ (1)
- PELDOR (1)
- PGE2 (1)
- PI3K (1)
- PID prevalence (1)
- PLX4032 (1)
- PLX4720 (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Pancreatitis (1)
- Pandemic (1)
- Panel testing (1)
- Parainfluenza (1)
- Particle and Resonance Production (1)
- Pathological complete response (1)
- Pathology (1)
- Patient safety (1)
- Patterns of care (1)
- Pb isotopes (1)
- Pb–Pb (1)
- Peritonitis (1)
- Personalized medicine (1)
- Perturbative methods (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- PillCamColon2 (1)
- Plant sciences (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Platelets (1)
- Polyps (1)
- Population-based screening (1)
- Portal veins (1)
- Post-Neoliberalismus (1)
- Poverty (1)
- Pre-emptive immunotherapy (1)
- Preoperative radiochemotherapy (1)
- Production Cross Section (1)
- Prognostic models (1)
- Properties of Hadrons (1)
- Prostaglandin (1)
- Prostate cancer (1)
- Protease inhibitor therapy (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Pseudo HE-images (1)
- Psoriasis vulgaris (1)
- Psychiatry (1)
- Pygmy Dipole Resonance (1)
- Pyogenic spondylodiscitis (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quasi-particle phonon model (1)
- Quinine (1)
- RMS (1)
- RNA induced silencing complex (1)
- RNA recognition (1)
- RNA, long noncoding (1)
- Radiation detectors (1)
- Radio continuum emission (1)
- Radio jets (1)
- Radiofrequency (1)
- Raman spectroscopy (1)
- Rapidity Range (1)
- Re-exploration (1)
- Reactions with relativistic radioactive beams (1)
- Reactive oxygen species (1)
- Recall rate (1)
- Rectal cancer (1)
- Red blood cell transfusion (1)
- Registries (1)
- Rehabilitation (1)
- Rehospitalization (1)
- Reintervention (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research Infrastructure (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- Respiratory infections (1)
- Respiratory syncytial virus (1)
- Retinal diseases (1)
- Rhaphipodini (1)
- Risk factor (1)
- Robotic tracking (1)
- Rome (1)
- SARS-CoV-2 (1)
- SCCHN (1)
- SD-OCT (1)
- SKALE score (1)
- SLC20A1 (1)
- SMAD (1)
- SPSS (1)
- SR-BI (1)
- STAMPE2 (1)
- STAR (1)
- SVR (1)
- Salivary gland carcinoma (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Seasonal variation (1)
- Second Punic War (1)
- Seed beetles (1)
- Seizure (1)
- Self-renewal (1)
- Semantics (1)
- Sequence alignment (1)
- Severe malaria (1)
- Shear viscosity (1)
- Single muons (1)
- Single particle decay spectroscopy (1)
- Small molecules (1)
- Social determinants (1)
- SoftDrop (1)
- Solar insolation (1)
- Sorafenib (1)
- Spectroscopic factors & electromagnetic moments (1)
- Spin alignment (1)
- Spine care (1)
- Splitting function (1)
- Sputum smear-negative (1)
- Standardization (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stentoplasty (1)
- Storage ring (1)
- Sunlight (1)
- Superinfection (1)
- Supermassive black holes (1)
- Superoxide (1)
- Surgical risk (1)
- Survival (1)
- Survival analysis (1)
- Synthetic (1)
- Systematic Uncertainty (1)
- TAVR (1)
- TB-therapy (1)
- TEMPO (1)
- TGFB-induced factor homeobox 1 (1)
- TGFβ (1)
- TGIF (1)
- TGR(mREN2)27 (1)
- TOR signalling (1)
- TR (1)
- Tailored medicine (1)
- Taxonomy (1)
- Technical data (1)
- Technique (1)
- Temozolomide (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Thoracic trauma (1)
- Thrombosis (1)
- Thromboxane (1)
- Time Projection Chamber (1)
- Timing (1)
- Tracking (1)
- Transcriptome analysis (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Trauma (1)
- Treatment (1)
- Trigger (1)
- Triple negative (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- UAV (1)
- USP28 (1)
- Upper respiratory tract infection (1)
- Uveal melanoma (1)
- VEGF (1)
- VEGFR (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- VRE (1)
- Vascular emergencies (1)
- Vector Boson Production (1)
- Veins (1)
- Vemurafenib (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Very long baseline interferometry (1)
- Vesicles (1)
- Vincristine (1)
- Vitreous samples (1)
- Wang resin (1)
- Western Mediterranean (1)
- Western blot (1)
- Western diet (1)
- WoMo score (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute decompensation (1)
- acute leukemia (1)
- acute-on-chronic liver failure (1)
- adaptive cardiac remodelling (1)
- adenocarcinoma (1)
- adjuvant chemotherapy (1)
- age (1)
- age-related macular degeneration (1)
- aging (1)
- alleles (1)
- alternative oxidase (1)
- amphiregulin (1)
- anaemia (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- angiogenesis (1)
- angiopoietin-2 (1)
- anterior chamber depth changes (1)
- antibiotic therapy (1)
- anticonvulsants (1)
- antiepileptic drugs (1)
- antifungal activity (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- aortic stenosis (1)
- argonaute protein (1)
- artifacts (1)
- ascites (1)
- astrocyte heterogeneity (1)
- atherosclerosis (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- axions (1)
- beetle species (1)
- biogeographic legaciese (1)
- bioindication (1)
- biological maturation (1)
- bipolar disorder (1)
- bladder cancer (1)
- bladder exstrophy-epispadias complex (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- boron (1)
- bryophyte (1)
- c-kit (1)
- cPLA2 (1)
- calcium-independent phospholipase A2β (1)
- calorimeter: electromagnetic (1)
- cancer (1)
- cancer immunotherapy (1)
- capture (1)
- carbapenem resistance (1)
- cardiac ischaemia‐reperfusion (1)
- cardiac magnetic resonance (1)
- cataract surgery (1)
- cell therapy (1)
- cell transplantation (1)
- cellular therapy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cerium (1)
- chemiluminescence (1)
- child (1)
- children and adolescents (1)
- chromosomal translocations (1)
- chronic viral hepatitis (1)
- cleavage of large RNA molecules (1)
- cleavage site selection (1)
- cloacal malformation (1)
- cognitive decline (1)
- collagen degradation marker (1)
- colorectal cancer (1)
- computed tomography (1)
- cone-beam computed tomography (CBCT) (1)
- consensus data set (1)
- conservation (1)
- copy number polymorphism (1)
- coronary disease (1)
- coumarin-4-ylmethyl (1)
- cross-section (1)
- cryo-EM (1)
- cryopreservation (1)
- cyclosporin A (1)
- cystic fibrosis (1)
- cytarabine dose (1)
- cytokine (1)
- cytotoxic T cells (1)
- cytotoxicity (1)
- dE/dx (1)
- dark matter experiments (1)
- data quality (1)
- decompressive craniectomy (1)
- depression (1)
- detector (1)
- dexamethasone (1)
- diabetic macular edema (1)
- disease prevalence (1)
- disease progression (1)
- distributed analysis (1)
- domestication (1)
- drone (1)
- dye labeling (1)
- dysphagia (1)
- early recognition (1)
- ectosomes (1)
- education (1)
- effective lens position (1)
- elderly patients (1)
- electroencephalography (EEG) (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- electron transport chain (1)
- electronics: readout (1)
- energy-dispersive x-ray spectroscopy (1)
- epigenomics (1)
- epilepsy (1)
- epiregulin (1)
- eutrophication (1)
- evolution (1)
- ex vivo expansion (1)
- excitation (1)
- exhaustion (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- extraskeletal (1)
- f-MLF (1)
- facial nerve functional outcome (1)
- feasibility study (1)
- federated feasibility queries (1)
- fibre: optical (1)
- fibrotest (1)
- financial literacy (1)
- fine spatial resolution remote sensing (1)
- fluocinolone acetonide (1)
- fluorescence in situ hybridization (FISH) (1)
- flurbiprofen (1)
- forest classification (1)
- forest functional similarity (1)
- formylation (1)
- fresh frozen plasma (1)
- functional genetics (1)
- functional outcome (1)
- fungal sinusitis (1)
- gap junction protein alpha 4-genotype (1)
- gene expression (1)
- gene flow (1)
- genes (1)
- genes for longevity (1)
- genetic generalized epilepsy (1)
- genetic phenotypes (1)
- genetics (1)
- genome (1)
- genotype (1)
- genotype determination (1)
- geriatric medicine (1)
- germ cell tumors (1)
- glioblastoma (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- growth inhibition (1)
- guanidine analogs (1)
- guidelines (1)
- habitat destruction (1)
- health data (1)
- hearing nerve (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- hepatitis c (1)
- high-dose chemotherapy (1)
- highly-charged ions (1)
- histology (1)
- host plants (1)
- human natural killer cell (1)
- hypertension and anti-hypertensive treatment (1)
- hypertension, pulmonary (1)
- immune checkpoint blockade (1)
- immune infiltration (1)
- immune therapy (1)
- immunity (1)
- immunocytochemistry (1)
- immunohistochemistry (1)
- immunosuppressive agent (1)
- improvement in quality of life (1)
- in silico simulation (1)
- infection control (1)
- inflammasome (1)
- inflammation (1)
- inflammatory markers (1)
- interferon regulatory factor 9 (IRF9) (1)
- interleukin-1β (1)
- interoperability (1)
- intracerebral hemorrhage (ICH) (1)
- invasive fungal infection (1)
- kidney formation (1)
- kidney function (1)
- lamotrigine (1)
- land use (1)
- lapatinib (1)
- levetiracetam (1)
- lichen (1)
- lichen extracts (1)
- liver (1)
- liver cirrhosis (1)
- liver fibrosis (1)
- liver metastasis (1)
- locked nucleic acids (1)
- long-term protection (1)
- long36 term protection (1)
- longitudinal follow-up after epilepsy surgery (1)
- lung disease phenotype (1)
- lung function (1)
- lymphoma (1)
- mRNA (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magic-angle spinning (1)
- mechanical accuracy (1)
- medical informatics (1)
- membrane proteins (1)
- methylprednisolone (1)
- miRNAs (1)
- microdosing (1)
- microparticles (1)
- microsurgical treatment (1)
- microvesicles (1)
- migration (1)
- minimal clinically important difference (1)
- minimal information requirements (1)
- mixed infection (1)
- molecular machines (1)
- mouse (1)
- mucormycetes (1)
- multicenter study (1)
- multidrug resistance (1)
- multilevel latent polynomial regression analysis (1)
- mycophenolic acid (1)
- myocardial fibrosis (1)
- n_TOF (1)
- natural killer cell (1)
- neoadjuvant therapy (1)
- neovascularization, physiologic (1)
- neuroblastoma (1)
- neutron (1)
- neutrophils (1)
- new species (1)
- nitrogen deposition (1)
- nomenclatural revision (1)
- non-invasive fibrosis assessment (1)
- nucleophilic substitution (1)
- nucleosynthesis (1)
- oligonucleotide (1)
- oligonucleotides (1)
- opportunity (1)
- ovary (1)
- oxLDL (1)
- p+p collisions (1)
- p-hydroxyphenacyl (1)
- p47phox (1)
- pandemic (1)
- patient data (1)
- pediatric (1)
- pediatric cancer (1)
- pediatric patients (1)
- pediatric solid tumors (1)
- perforin (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- phantom study (1)
- pharmacoresistance (1)
- phenotype (1)
- phenotype/genotype relation (1)
- photoacid generator (1)
- photolabile protection (1)
- photolysis (1)
- phylogenetic community distance (1)
- phylogeny (1)
- plant height (1)
- platelet lysate (1)
- platinum-based chemotherapy (1)
- point shear wave elastography (1)
- polygenic risk score (1)
- portosystemic shunt (1)
- post-transplantation lymphoproliferative disease (1)
- precision medicine (1)
- predictive biomarkers (1)
- predictor (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- prognosis (1)
- prognostic biomarker (1)
- propagation of inequality (1)
- proteasomal processing escape (1)
- proteasome (1)
- pseudoexfoliative syndrome (1)
- psoriasis (1)
- pull-down (1)
- pulmonary embolism (1)
- quantum electrodynamics test (1)
- quark gluon plasma (1)
- query (1)
- radical reactions (1)
- reactive oxygen species (1)
- recurrence pattern (1)
- redox chemistry (1)
- registry for primary immunodeficiency (1)
- relativistic collisions (1)
- reliable change index (1)
- renin-angiotensin system (1)
- reproducibility (1)
- retrospective trial (1)
- rhabdomyosarcoma (1)
- rigor (1)
- risk assessment (1)
- robot-guided stereotaxy (1)
- rosacea (1)
- s-process (1)
- scar (1)
- schizophrenia (1)
- screening routine (1)
- seizures (1)
- senescence (1)
- sequence alignment (1)
- sex (1)
- signal transduction (1)
- silver coinage (1)
- single nucleotide polymorphism (1)
- single subject classification (1)
- smart home (1)
- smart living (1)
- social identity (1)
- social interactions (1)
- sodium bituminosulfonate (1)
- soil nutrients (1)
- solar physics (1)
- solitary pulmonary nodule (1)
- species richness (1)
- specificity of cleavage (1)
- spectra (1)
- speech and language pathologist (1)
- spontaneous portosystemic shunt (1)
- squamous cell carcinoma (1)
- stage II/III colorectal cancer (1)
- standardization (1)
- standardized regression-based change norms (1)
- stereotactic frame (1)
- stereotactic neurosurgery (1)
- stratification (1)
- stroke (1)
- strong Coulomb field (1)
- structural biology (1)
- structure-from-motion photogrammetry (1)
- subdural hematoma (1)
- subvalent compounds (1)
- surgery (1)
- systematics (1)
- talent development (1)
- talent identification (1)
- targeted therapy (1)
- taxonomy (1)
- telmisartan (1)
- temporal classification (1)
- testis (1)
- therapeutic anticoagulation (1)
- tomography (1)
- trace elements (1)
- trans-Golgi network (1)
- transbronchial biopsy (TBB) (1)
- transcatheter aortic valve replacement (1)
- transfemoral (1)
- transient elastography (1)
- translocation partner genes (1)
- transmission (1)
- trastuzumab (1)
- treatment resistance (1)
- tropical forests (1)
- tumor microenvironment (1)
- tumor microenvironment (TME) (1)
- type I interferons (IFNs) (1)
- umpolung (1)
- urinary tract development (1)
- urothelial carcinoma (1)
- uveal melanoma (1)
- vaccination (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- valproic acid (1)
- vascular calcification (1)
- vascular dysfunction and inflammation (1)
- vascular endothelial growth factor (1)
- vegetation classification (1)
- vegetation-plot data (1)
- vemurafenib (1)
- versican (VCAN) (1)
- vestibular schwannoma (1)
- viability (1)
- water solubility (1)
- wealth inequality (1)
- web of things (1)
- white and brown dwarfs (1)
- whole-genome sequencing (1)
- women (1)
- x-ray techniques (1)
- youth football (1)
- zebrafish development (1)
- ΔNp63 (1)
- γ-ray spectroscopy (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1213)
- Frankfurt Institute for Advanced Studies (FIAS) (998)
- Informatik (924)
- Medizin (212)
- Geowissenschaften (28)
- ELEMENTS (21)
- Biochemie und Chemie (17)
- Biowissenschaften (14)
- Senckenbergische Naturforschende Gesellschaft (10)
- Institut für Ökologie, Evolution und Diversität (9)
Organoboranes are among the most versatile and widely used reagents in synthetic chemistry. A significant further expansion of their application spectrum would be achievable if boron-containing reactive intermediates capable of inserting into C–H bonds or performing nucleophilic substitution reactions were readily available. However, current progress in the field is still hampered by a lack of universal design concepts and mechanistic understanding. Herein we report that the doubly arylene-bridged diborane(6) 1H2 and its B[double bond, length as m-dash]B-bonded formal deprotonation product Li2[1] can activate the particularly inert C(sp3)–H bonds of added H3CLi and H3CCl, respectively. The first case involves the attack of [H3C]− on a Lewis-acidic boron center, whereas the second case follows a polarity-inverted pathway with nucleophilic attack of the B[double bond, length as m-dash]B double bond on H3CCl. Mechanistic details were elucidated by means of deuterium-labeled reagents, a radical clock, α,ω-dihaloalkane substrates, the experimental identification of key intermediates, and quantum-chemical calculations. It turned out that both systems, H3CLi/1H2 and H3CCl/Li2[1], ultimately funnel into the same reaction pathway, which likely proceeds past a borylene-type intermediate and requires the cooperative interaction of both boron atoms.
Background: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1), intended to induce targeted immune responses.
Methods: We describe a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy. Patients were stratified into three strata (1: non-squamous NSCLC, no epidermal growth factor receptor (EGFR) mutation, PR/SD after ≥4 cycles of platinum- and pemetrexed-based treatment [n = 16]; 2: squamous NSCLC, PR/SD after ≥4 cycles of platinum-based and non-platinum compound treatment [n = 8]; 3: non-squamous NSCLC, EGFR mutation, PR/SD after ≥3 and ≤ 6 months EGFR-tyrosine kinase inhibitor (TKI) treatment [n = 2]). Patients received intradermal BI1361849, local radiation (4 × 5 Gy), then BI1361849 until disease progression. Strata 1 and 3 also had maintenance pemetrexed or continued EGFR-TKI therapy, respectively. The primary endpoint was evaluation of safety; secondary objectives included assessment of clinical efficacy (every 6 weeks during treatment) and of immune response (on Days 1 [baseline], 19 and 61).
Results: Study treatment was well tolerated; injection site reactions and flu-like symptoms were the most common BI1361849-related adverse events. Three patients had grade 3 BI1361849-related adverse events (fatigue, pyrexia); there was one grade 3 radiation-related event (dysphagia). In comparison to baseline, immunomonitoring revealed increased BI1361849 antigen-specific immune responses in the majority of patients (84%), whereby antigen-specific antibody levels were increased in 80% and functional T cells in 40% of patients, and involvement of multiple antigen specificities was evident in 52% of patients. One patient had a partial response in combination with pemetrexed maintenance, and 46.2% achieved stable disease as best overall response. Best overall response was SD in 57.7% for target lesions.
Conclusion: The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
Trial registration: ClinicalTrials.gov identifier: NCT01915524.
Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem to cure the patients, and it is unknown, when and how to stop vemurafenib treatment. We present a girl with severe multisystem LCH who responded only to vemurafenib. After 8 months of treatment, vemurafenib was tapered and replaced by prednisone and vinblastine, a strategy which has not been described to date. Despite chemotherapy, early relapse occurred, but remission was achieved by re-institution of vemurafenib. Further investigation needs to address the optimal duration of vemurafenib therapy in LCH and whether and which chemotherapeutic regimen may prevent disease relapse after cessation of vemurafenib.
Double reduction of the THF adduct of 9H-9-borafluorene (1⋅THF) with excess alkali metal affords the dianion salts M2[1] in essentially quantitative yields (M=Li–K). Even though the added charge is stabilized through π delocalization, [1]2− acts as a formal boron nucleophile toward organoboron (1⋅THF) and tetrel halide electrophiles (MeCl, Et3SiCl, Me3SnCl) to form B−B/C/Si/Sn bonds. The substrate dependence of open-shell versus closed-shell pathways has been investigated.
Two subvalent, redox-active diborane(4) anions, [3]4− and [3]2−, carrying exceptionally high negative charge densities are reported: Reduction of 9-methoxy-9-borafluorene with Li granules without stirring leads to the crystallization of the B(sp3)−B(sp2) diborane(5) anion salt Li[5]. [5]− contains a 2,2′-biphenyldiyl-bridged B−B core, a chelating 2,2′-biphenyldiyl moiety, and a MeO substituent. Reduction of Li[5] with Na metal gives the Na+ salt of the tetraanion [3]4− in which two doubly reduced 9-borafluorenyl fragments are linked via a B−B single bond. Comproportionation of Li[5] and Na4[3] quantitatively furnishes the diborane(4) dianion salt Na2[3], the doubly boron-doped congener of 9,9′-bis(fluorenylidene). Under acid catalysis, Na2[3] undergoes a formal Stone–Wales rearrangement to yield a dibenzo[g,p]chrysene derivative with B=B core. Na2[3] shows boron-centered nucleophilicity toward n-butyl chloride. Na4[3] produces bright blue chemiluminescence when exposed to air.
Pediatric patients with recurrent, refractory or advanced soft tissue sarcoma (STS) who are simultaneously showing signs of cumulative treatment toxicity are in need of novel therapies. In this preclinical analysis, we identified ErbB2 as a targetable antigen on STS cells and used cytokine-induced killer (CIK) cells transduced with the lentiviral 2nd-generation chimeric antigen receptor (CAR) vector pS-5.28.z-IEW to target ErbB2-positive tumors. Solely CIK cell subsets with the CD3+ T cell phenotype showed up to 85% cell surface expression of the respective CAR. A comparison of wildtype (WT), mock-vector and ErbB2-CAR-CIK cells showed, that engineered cells exhibited diminished in vitro expansion, retained WT CIK cell phenotype with higher percentages of differentiated effector memory/effector cells. Activating natural killer (NK) cell receptor NKG2D-restricted target cell recognition and killing of WT and ErbB2-CAR-CIK cells was maintained against ErbB2-negative tumors, while ErbB2-CAR-CIK cells demonstrated significantly increased cytotoxicity against ErbB2-positive targets, including primary tumors. ErbB2-CAR- but not WT CIK cells proliferated, infiltrated and efficiently lysed tumor cell monolayers as well as 3D tumor spheroids.
Here, we demonstrate a potential cell therapeutic approach using ErbB2-CAR-CIK cells for the recognition and elimination of tumor cells expressing ErbB2, which we identified as a targetable antigen on high-risk STS cells.
Background: Prolonged immunosuppression or delayed T-cell recovery may favor Epstein-Barr virus (EBV) infection or reactivation after allogeneic hematopoietic stem cell transplantation (HSCT), which can lead to post-transplant lymphoproliferative disease (PTLD) and high-grade malignant B-cell lymphoma. Cytokine-induced killer (CIK) cells with dual specific anti-tumor and virus-specific cellular immunity may be applied in this context.
Methods: CIK cells with EBV-specificity were generated from peripheral blood mononuclear cells (PBMCs), expanded in the presence of interferon-γ, anti-CD3, interleukin (IL)-2 and IL-15 and were pulsed twice with EBV consensus peptide pool. CIK cells with EBV-specificity and conventional CIK cells were phenotypically and functionally analyzed. Additionally, CIK cells with EBV-specificity were applied to a patient with EBV-related PTLD rapidly progressing to highly aggressive B-cell lymphoma on a compassionate use basis after approval and agreement by the regulatory authorities.
Results: Pre-clinical analysis showed that generation of CIK cells with EBV-specificity was feasible. In vitro cytotoxicity analyses showed increased lysis of EBV-positive target cells, enhanced proliferative capacity and increased secretion of cytolytic and proinflammatory cytokines in the presence of EBV peptide-displaying target cells. In addition, 1 week after infusion of CIK cells with EBV-specificity, the patient's highly aggressive B-cell lymphoma persistently disappeared. CIK cells with EBV-specificity remained detectable for up to 32 days after infusion and infusion did not result in acute toxicity.
Discussion: The transfer of both anti-cancer potential and T-cell memory against EBV infection provided by EBV peptide-induced CIK cells might be considered a therapy for EBV-related PTLD.
Neuroblastoma (NB) is the most common solid extracranial tumor in childhood. Despite therapeutic progress, prognosis in high-risk NB is poor and innovative therapies are urgently needed. Therefore, we addressed the potential cytotoxic capacity of interleukin (IL)-activated natural killer (NK) cells compared to cytokine-induced killer (CIK) cells for the treatment of NB. NK cells were isolated from peripheral blood mononuclear cells (PBMCs) by indirect CD56-enrichment or CD3/CD19-depletion and expanded with different cytokine combinations, such as IL-2, IL-15, and/or IL-21 under feeder-cell free conditions. CIK cells were generated from PBMCs by ex vivo stimulation with interferon-γ, IL-2, OKT-3, and IL-15. Comparative analysis of expansion rate, purity, phenotype and cytotoxicity was performed. CD56-enriched NK cells showed a median expansion rate of 4.3-fold with up to 99% NK cell content. The cell product after CD3/CD19-depletion consisted of a median 43.5% NK cells that expanded significantly faster reaching also 99% of NK cell purity. After 10–12 days of expansion, both NK cell preparations showed a significantly higher median cytotoxic capacity against NB cells relative to CIK cells. Remarkably, these NK cells were also capable of efficiently killing NB spheroidal 3D culture in long-term cytotoxicity assays. Further optimization using a novel NK cell culture medium and a prolonged culturing procedure after CD3/CD19-depletion for up to 15 days enhanced the expansion rate up to 24.4-fold by maintaining the cytotoxic potential. Addition of an IL-21 boost prior to harvesting significantly increased the cytotoxicity. The final cell product consisted for the major part of CD16−, NCR-expressing, poly-functional NK cells with regard to cytokine production, CD107a degranulation and antitumor capacity. In summary, our study revealed that NK cells have a significantly higher cytotoxic potential to combat NB than CIK cell products, especially following the synergistic use of IL-15 and IL-21 for NK cell activation. Therefore, the use of IL-15+IL-21 expanded NK cells generated from CD3/CD19-depleted apheresis products seems to be highly promising as an immunotherapy in combination with haploidentical stem cell transplantation (SCT) for high-risk NB patients.
Multidrug-resistant Gram-negative bacteria (MDR GNB) were found to colonise 60.8% (95% confidence interval: 52.3–68.9) of 143 refugee patients mainly from Syria (47), Afghanistan (29), and Somalia (14) admitted to the University Hospital Frankfurt, Germany, between June and December 2015. This percentage exceeds the prevalence of MDR GNB in resident patients four–fold. Healthcare personnel should be aware of this and the need to implement or adapt adequate infection control measures.
Ecological networks are more sensitive to plant than to animal extinction under climate change
(2016)
Impacts of climate change on individual species are increasingly well documented, but we lack understanding of how these effects propagate through ecological communities. Here we combine species distribution models with ecological network analyses to test potential impacts of climate change on >700 plant and animal species in pollination and seed-dispersal networks from central Europe. We discover that animal species that interact with a low diversity of plant species have narrow climatic niches and are most vulnerable to climate change. In contrast, biotic specialization of plants is not related to climatic niche breadth and vulnerability. A simulation model incorporating different scenarios of species coextinction and capacities for partner switches shows that projected plant extinctions under climate change are more likely to trigger animal coextinctions than vice versa. This result demonstrates that impacts of climate change on biodiversity can be amplified via extinction cascades from plants to animals in ecological networks.
From July 2002 to March 2004 the Michelson Interferometer for Passive Atmospheric Sounding (MIPAS) aboard the European Space Agency´s Environmental Satellite (Envisat) measured nearly continuously mid infrared limb radiance spectra. These measurements are utilised to retrieve the global distribution of the chlorofluorocarbon CFC-11 by applying a new fast forward model for Envisat MIPAS and an accompanying optimal estimation retrieval processor. A detailed analysis shows that the total retrieval errors of the individual CFC-11 volume mixing ratios are typically below 10% in the altitude range 10 to 25 km and that the systematic components dominate. Contribution of a priori information to the retrieval results are less than 5 to 10% and the vertical resolution of the observations is about 3 to 4 km in the same vertical range. The data are successfully validated by comparison with several other space experiments, an air-borne in-situ instrument, measurements from ground-based networks, and independent Envisat MIPAS analyses. The retrieval results from 425 000 Envisat MIPAS limb scans are compiled to provide a new climatological data set of CFC-11. The climatology shows significantly lower CFC-11 abundances in the lower stratosphere compared with the Reference Atmospheres for MIPAS (RAMstan V3.1) climatology. Depending on the atmospheric conditions the differences between the climatologies are up to 30 to 110 ppt (45 to 150%) at 19 to 27 km altitude. Additionally, time series of CFC-11 mean abundance and variability for five latitudinal bands are presented. The observed CFC-11 distributions can be explained by the residual mean circulation and large-scale eddy-transports in the upper troposphere and lower stratosphere. The new CFC-11 data set is well suited for further scientific studies.
Background: The most frequent therapy of hydrocephalus is the implantation of ventriculoperitoneal shunts for diverting cerebrospinal fluid from the ventricles into the peritoneum. We compared two adjustable valves, the proGAV and proGAV 2.0, for complications which resulted in revision operations.
Methods: Four hundred patients who underwent primary shunt implantation between 2014 and 2020 were analyzed for overall revision rate, one-year revision rate, revision free survival and overall survival observing patient age group, gender, etiology of hydrocephalus, implantation site, prior diversion of cerebrospinal fluid and cause of revision.
Results: All data were available of all 400 patients (female/male 208/192). Overall, 99 patients underwent revision surgery after primary implantation. ProGAV valve was implanted in 283 patients, proGAV 2.0 in 117 patients. There was no significant difference between the two shunt valves concerning revision rate (p=0.8069), one-year revision rate (p=0.9077), revision free survival (p=0.6921) and overall survival (p=0.3232). Furthermore, regarding one-year revision rate, we observed no significant difference between the two shunt valves in pediatric patients (40.7% vs 27.6%; p=0.2247). Revision operation had to be performed more frequently in pediatric patients (46.6% vs 24.8%; p=0.0093) with a significant higher number of total revisions with proGAV than proGAV 2.0 (55.9% vs. 27.6%; p=0.0110) most likely due to longer follow up in the proGAV -group.
Conclusion: According to the target variables we analyzed, aside from lifetime revision rate in pediatric patients there is no significant difference between the two shunt valves. From our subjective point of view, implantation of the newer proGAV 2.0 valve is preferable due to higher adjustment comfort for both patients and physicians.
This paper uses unique administrative data and a quasi-field experiment of exogenous allocation in Sweden to estimate medium- and longer-run effects on financial behavior from exposure to financially literate neighbors. It contributes evidence of causal impact of exposure and of a social multiplier of financial knowledge, but also of unfavorable distributional aspects of externalities. Exposure promotes saving in private retirement accounts and stockholding, especially when neighbors have economics or business education, but only for educated households and when interaction possibilities are substantial. Findings point to transfer of knowledge rather than mere imitation or effects through labor, education, or mobility channels.
The authors present evidence of a new propagation mechanism for wealth inequality, based on differential responses, by education, to greater inequality at the start of economic life. The paper is motivated by a novel positive cross-country relationship between wealth inequality and perceptions of opportunity and fairness, which holds only for the more educated. Using unique administrative micro data and a quasi-field experiment of exogenous allocation of households, the authors find that exposure to a greater top 10% wealth share at the start of economic life in the country leads only the more educated placed in locations with above-median wealth mobility to attain higher wealth levels and position in the cohort-specific wealth distribution later on. Underlying this effect is greater participation in risky financial and real assets and in self-employment, with no evidence for a labor income, unemployment risk, or human capital investment channel. This differential response is robust to controlling for initial exposure to fixed or other time-varying local features, including income inequality, and consistent with self-fulfilling responses of the more educated to perceived opportunities, without evidence of imitation or learning from those at the top.
The Eurozone fiscal crisis has created pressure for institutional harmonization, but skeptics argue that cultural predispositions can prevent convergence in behavior. Our paper derives a robust cultural classification of European countries and utilizes unique data on natives and immigrants to Sweden. Classification based on genetic distance or on Hofstede’s cultural dimensions fails to identify a single ‘southern’ culture but points to a ‘northern’ culture. Significant differences in financial behavior are found across cultural groups, controlling for household characteristics. Financial behavior tends to converge with longer exposure to common institutions, but is slowed down by longer exposure to original institutions.
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 3-year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. (trial registered at www.clinicaltrials.gov: NCT00355862) (EudraCT Number: 2005-005362-36)
The New World genus Dysmerus Casey, currently with one valid species, is revised. Lectotypes are designated for two species, Dysmerus caseyi (Grouvelle), new status, and Dysmerus sulcicollis Grouvelle, new status. Both are revived from synonymy with D. basalis Casey. Twelve new species are described: Dysmerus boliviensis Thomas, new species, Dysmerus curvicornis Thomas, new species, Dysmerus genaspinosus Thomas, new species, Dysmerus hamaticornis Thomas, new species, Dysmerus impolitus Thomas, new species, Dysmerus skelleyi Thomas, new species, Dysmerus mexicanus Thomas, new species, Dysmerus monstrosus Thomas, new species, Dysmerus politus Thomas, new species, Dysmerus rondoniensis Thomas, new species, Dysmerus symphilus Thomas, new species, and Dysmerus trinidadensis Thomas, new species. A key to adults of the species and illustrations are provided.
Australophanus, new genus, is described and illustrated for Cryptamorpha redtenbacheri (Reitter). Platamus Erichson is synonymized under Telephanus Erichson, new synonymy. Euplatamus Sharp, new status, replaces Platamus Erichson as the genus name. Type species are designated for Aplatamus Grouvelle and Euplatamus Sharp. Telephanus velox (Haldeman) is synonymized under Telephanus atricapillus Erichson. A diagnosis of the tribe Telephanini, a key to the described telephanine genera of the world is presented, and a phylogeny of the family Silvanidae is proposed.